Efficacy and safety of apatinib as third-or further-line therapy for patients with advanced NSCLC: a retrospective study
J Liang, W Gu, J Jin, H Zhang, Z Chen… - Therapeutic …, 2020 - journals.sagepub.com
… has been demonstrated for many cancers, including non-small-cell lung cancer (NSCLC).
The … the clinical efficacy of apatinib in patients with advanced NSCLC. Patients and methods: …
The … the clinical efficacy of apatinib in patients with advanced NSCLC. Patients and methods: …
Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
Q Jiang, NL Zhang, DY Ma, BX Tan, X Hu, XD Fang - Medicine, 2019 - journals.lww.com
… [1] Non-small cell lung cancer (NSCLC) accounts for about 80% of … The safety and efficacy
of apatinib in combination with docetaxel in these patients were evaluated in this research. …
of apatinib in combination with docetaxel in these patients were evaluated in this research. …
The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
J Wang, D Huang, W Yang, Q Song, Y Jia… - Frontiers in …, 2022 - frontiersin.org
… In summary, our research demonstrated the high efficacy and safety of Apatinib in
patients with advanced NSCLC, especially when they suffered progression after first-line …
patients with advanced NSCLC, especially when they suffered progression after first-line …
Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis
S Qin, X Han, Z Li - Oncology Letters, 2023 - spandidos-publications.com
… regarding its use in non‑small cell lung cancer (NSCLC) … efficacy and safety of the use of
apatinib plus chemotherapy vs. chemotherapy alone for the treatment of patients with advanced‑…
apatinib plus chemotherapy vs. chemotherapy alone for the treatment of patients with advanced‑…
[HTML][HTML] Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
G Gao, J Zhao, S Ren, Y Wang, G Chen… - Annals of …, 2022 - ncbi.nlm.nih.gov
… in patients with squamous NSCLC. This study assessed the efficacy and safety of camrelizumab
plus apatinib (… ) as second-line treatment in patients with advanced squamous NSCLC. …
plus apatinib (… ) as second-line treatment in patients with advanced squamous NSCLC. …
Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta …
Z Li, Z Liu, Y Wu, H Li, Z Sun, C Han, X Zhang… - … Cancer, 2021 - Wiley Online Library
… Patients: advanced non-small cell lung cancer with pathology or PE-CT confirmation.
Intervention: apatinib alone or apatinib plus paclitaxel/docetaxel. Control: paclitaxel/docetaxel. …
Intervention: apatinib alone or apatinib plus paclitaxel/docetaxel. Control: paclitaxel/docetaxel. …
Efficacy and safety of apatinib plus vinorelbine in patients with wild-type advanced non–small cell lung cancer after second-line treatment failure: a nonrandomized …
X Zhang, Y Xiong, Q Xia, F Wu, L Liu, Y Zhou… - JAMA Network …, 2020 - jamanetwork.com
… apatinib and oral vinorelbine is potentially efficacious in the third-line setting and beyond
among patients with variation-negative advanced … option in this subset of patients. In our cohort, …
among patients with variation-negative advanced … option in this subset of patients. In our cohort, …
[HTML][HTML] Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic …
G Gao, J Ni, Y Wang, S Ren, Z Liu, G Chen… - … Lung Cancer …, 2022 - ncbi.nlm.nih.gov
… Camrelizumab plus apatinib shows … -pretreated patients with advanced non-small cell lung
cancer (NSCLC); however, clinical benefits from this combination regimen in NSCLC patients …
cancer (NSCLC); however, clinical benefits from this combination regimen in NSCLC patients …
Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer
J Li, X Tong, H Li - Indian Journal of Cancer, 2020 - journals.lww.com
… role in elderly patients remains unclear. In this study, we focused on elderly NSCLC patients,
and explored the efficacy and safety of apatinib as monotherapy when patients had failed …
and explored the efficacy and safety of apatinib as monotherapy when patients had failed …
Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy
C Zhou, Y Wang, J Zhao, G Chen, Z Liu, K Gu… - Clinical Cancer …, 2021 - AACR
… infiltration of CD8 + T cells and reducing recruitment of tumor-associated macrophages.
We … this combination in pretreated patients with advanced non–small cell lung cancer (NSCLC). …
We … this combination in pretreated patients with advanced non–small cell lung cancer (NSCLC). …